The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Bio Europe Spring 2022
March 28-31, 2022
We hope you enjoyed the BIO-EUROPE SPRING® 2022 virtual event, where our Subject Matter Experts provided key insights on the following hot topic:
Next generation biologics – manufacturing and supply strategies to accelerate time to market
Recent advances in technology have seen the development of many new types of biologics that have been particularly effective at targeting specific diseases. Increased complexities may lead to technical challenges resulting in longer CMC development timelines, a delay to clinical trials, and delayed commercial launches.
Points of discussion during this fireside chat:
- Best practices in managing complexities associated with next generation biologics development
- Formulation development and purification strategies to increase throughput, reduce operating costs and development timelines
- How to scale projects from early development through to large scale biologics manufacturing via 2k, 5K and up to 12.5K bioreactor technologies
- Applying a streamlined process, end-to-end, to accelerate time to market